dexamethasone + rituximab + cyclosporine + intravenous immunoglobulin

This is a combination therapy consisting of four agents—dexamethasone, rituximab, cyclosporine, and intravenous immunoglobulin (IVIG)—used primarily for the treatment of immune-mediated disorders such as immune thrombocytopenia (ITP) and other refractory autoimmune conditions. - **Dexamethasone** is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects, acting mainly through glucocorticoid receptor agonism to suppress multiple inflammatory pathways. - **Rituximab** is a chimeric monoclonal antibody targeting CD20 on B lymphocytes, leading to B-cell depletion via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity[3]. - **Cyclosporine** is an immunosuppressant that inhibits calcineurin, thereby blocking T-cell activation by preventing interleukin-2 transcription[9]. - **Intravenous immunoglobulin (IVIG)** consists of pooled IgG antibodies from donors; it exerts broad immunomodulatory effects including Fc receptor blockade on phagocytes, modulation of complement activation, neutralization of autoantibodies, and regulation of cytokines. This multi-agent regimen aims to simultaneously suppress different arms of the immune system—B cells (rituximab), T cells (cycloscoprine), innate immunity/modulation (IVIG), and general inflammation/immunity (dexamethasone)—to achieve rapid disease control in severe or refractory cases. The combination has been studied in ITP with promising results for inducing durable remissions[1][2][7].

Other names

DEX Combined With RTX, CSA and IVIGDexamethasone, Rituximab, Cyclosporin, and IVIG Combination